Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Diabetes. Dec 15, 2013; 4(6): 365-371
Published online Dec 15, 2013. doi: 10.4239/wjd.v4.i6.365
Published online Dec 15, 2013. doi: 10.4239/wjd.v4.i6.365
Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia
Anastazia Kei, Evangelos Liberopoulos, Moses Elisaf, Department of Internal Medicine, University of Ioannina Medical School, 45110 Ioannina, Greece
Author contributions: Kei A was responsible for enrolment and assignment patients to interventions, data collection and analysis/interpretation, statistics, writing manuscript draft; Elisaf M and Liberopoulos E designed the study, edited and approved the article.
Correspondence to: Moses Elisaf, MD, FRSH, FASA, FISA, Professor of Internal Medicine, Department of Internal Medicine, University of Ioannina Medical School, Stavrou Niarchou Str., 45110 Ioannina, Greece. egepi@cc.uoi.gr
Telephone: +30-265-1007509 Fax: +30-265-1007016
Received: April 4, 2013
Revised: October 21, 2013
Accepted: November 2, 2013
Published online: December 15, 2013
Processing time: 254 Days and 15.6 Hours
Revised: October 21, 2013
Accepted: November 2, 2013
Published online: December 15, 2013
Processing time: 254 Days and 15.6 Hours
Core Tip
Core tip: In this study both addition of extended release nicotinic acid/laropiprant and switch to the highest dose of rosuvastatin deteriorated glycemic profile in patients with mixed dyslipidemia who were inadequately controlled with a standard statin dose. Add-on fenofibrate, on the other hand, seems to increase insulin sensitivity. Larger prospective studies should address the effect of these treatment interventions on new onset diabetes incidence and cardiovascular disease risk.